At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,800 enrolled
Drug / intervention
Takeda's Tetravalent Dengue Vaccine Candidate (TDV) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America
In Brief
A Phase 2 clinical trial evaluating Takeda's Tetravalent Dengue Vaccine Candidate (TDV) and TDV Placebo for Dengue Fever. Completed, enrolled 1,800 participants across 3 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and \<18 years of age living in dengue endemic countries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDengue Fever
CountriesDominican Republic, Panama, Philippines
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedNov 2014
Enrollment StartDec 2014
Primary CompletionFeb 2019
TodayJul 2026
First PostedNov 26, 2014
Enrollment StartDec 5, 2014
Primary CompletionFeb 18, 2019
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 11.6 years ago
Interventions
Takeda's Tetravalent Dengue Vaccine Candidate (TDV)biological
TDV subcutaneous injection
TDV Placebobiological
Placebo-matching vaccine